SEC Form 4 · accession 0001250853-18-000013
Kindred Biosciences, Inc. · KIN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Raymond Townsend
Director
Period of report
Jan 2, 2018
Accepted (ET)
Jan 4, 2018 · 8:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001561743
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 2, 2018 | M | 6,419 | $3.45 | A | 18,419 | D | |
| Common Stock | Jan 2, 2018 | S | 6,419 | $9.45 | D | 12,000 | D | |
| Common Stock | Jan 2, 2018 | M | 11,142 | $3.45 | A | 23,142 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $3.45 | Jan 2, 2018 | M | 6,419 | D | — | Jan 8, 2026 | Common Stock | 6,419 | 37,581 | D |
| Stock Option (right to buy)F2 | $3.45 | Jan 2, 2018 | M | 11,142 | D | — | Jan 8, 2026 | Common Stock | 11,142 | 26,439 | D |
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 30, 2017.
- F2The option vested 25% quarterly following January 8, 2016, the date of grant.